How to book a medical appointment in Shanghai?

You can book through our online form, email, WeChat, or live chat. We will arrange the appointment within 24 hours and provide full assistance throughout your medical journey.

What languages do you support?

We provide full support in English, Russian, Chinese, Korean, and Japanese. All medical translations are handled by professional medical interpreters.

What are the payment methods?

Medical fees are paid directly to the hospital. Service fees can be paid via bank transfer, WeChat Pay, Alipay, or international wire transfer.

Do you help with visa arrangements?

Yes, we provide complete visa guidance and invitation letters for medical tourism to China.

Which hospitals do you partner with?

We partner with top-tier hospitals in Shanghai including Jiahui International Hospital, Huashan Hospital, Ruijin Hospital, and other leading medical institutions.

Ovarian Cancer Treatment in Shanghai: 2026 International Patient Guide

Ovarian Cancer in Shanghai

Ovarian cancer has the highest mortality among gynecologic malignancies. Shanghai's centers offer world-class cytoreductive surgery (with goal of no residual disease), hyperthermic intraperitoneal chemotherapy (HIPEC), and PARP inhibitor maintenance therapy.

Top Hospitals

Fudan University Shanghai Cancer Center (FUSCC) — Comprehensive gynecologic oncology with high-volume cytoreductive surgery.

Obstetrics & Gynecology Hospital of Fudan (Red House Hospital / 红房子) — Top gynecology specialty hospital.

Renji Hospital — Gynecologic oncology program.

Shanghai First Maternity and Infant Hospital — Fertility-sparing approaches for young patients.

Treatment Strategy

Initial debulking surgery: Goal is R0 (no gross residual disease) — the strongest prognostic factor. Complex procedures may include bowel resection, peritonectomy, diaphragm stripping.

Neoadjuvant chemotherapy (NACT) + interval debulking: For patients unsuitable for primary surgery.

HIPEC: Can be combined with interval debulking surgery after NACT in selected patients.

Maintenance therapy: PARP inhibitors (olaparib, niraparib, pamiparib — Chinese-developed) based on BRCA and HRD status.

Recurrent disease: Bevacizumab, rechallenge with platinum, PARP inhibitor if not previously used, clinical trials.

BRCA and Genetic Testing

All ovarian cancer patients should receive BRCA1/2 testing and HRD assessment to guide PARP inhibitor eligibility. Shanghai centers offer rapid genetic counseling and testing.

Cost Reference

Cytoreductive surgery + HIPEC: ¥100,000–200,000. Chemotherapy (carboplatin + paclitaxel): ¥10,000–20,000/cycle. PARP inhibitor maintenance: ¥15,000–40,000/month (pamiparib and other Chinese PARP inhibitors at lower end).